via University at Buffalo
Model could support the assessment of long-term chronic drug therapies and help clinicians develop more effective treatments for complex diseases
Using artificial intelligence, a team of University at Buffalo researchers has developed a novel system that models the progression of chronic diseases as patients age.
Published in Oct. in the Journal of Pharmacokinetics and Pharmacodynamics, the model assesses metabolic and cardiovascular biomarkers – measurable biological processes such as cholesterol levels, body mass index, glucose and blood pressure – to calculate health status and disease risks across a patient’s lifespan.
The findings are critical due to the increased risk of developing metabolic and cardiovascular diseases with aging, a process that has adverse effects on cellular, psychological and behavioral processes.
“There is an unmet need for scalable approaches that can provide guidance for pharmaceutical care across the lifespan in the presence of aging and chronic co-morbidities,” says lead author Murali Ramanathan, PhD, professor of pharmaceutical sciences in the UB School of Pharmacy and Pharmaceutical Sciences. “This knowledge gap may be potentially bridged by innovative disease progression modeling.”
The model could facilitate the assessment of long-term chronic drug therapies, and help clinicians monitor treatment responses for conditions such as diabetes, high cholesterol and high blood pressure, which become more frequent with age, says Ramanathan.
Additional investigators include first author and UB School of Pharmacy and Pharmaceutical Sciences alumnus Mason McComb, PhD; Rachael Hageman Blair, PhD, associate professor of biostatistics in the UB School of Public Health and Health Professions; and Martin Lysy, PhD, associate professor of statistics and actuarial science at the University of Waterloo.
The research examined data from three case studies within the third National Health and Nutrition Examination Survey (NHANES) that assessed the metabolic and cardiovascular biomarkers of nearly 40,000 people in the United States.
Biomarkers, which also include measurements such as temperature, body weight and height, are used to diagnose, treat and monitor overall health and numerous diseases.
The researchers examined seven metabolic biomarkers: body mass index, waist-to-hip ratio, total cholesterol, high-density lipoprotein cholesterol, triglycerides, glucose and glycohemoglobin. The cardiovascular biomarkers examined include systolic and diastolic blood pressure, pulse rate and homocysteine.
By analyzing changes in metabolic and cardiovascular biomarkers, the model “learns” how aging affects these measurements. With machine learning, the system uses a memory of previous biomarker levels to predict future measurements, which ultimately reveal how metabolic and cardiovascular diseases progress over time.
Original Article: AI-powered computer model predicts disease progression during aging
More from: University at Buffalo | University of Waterloo
The Latest on: Progression of chronic diseases
- My cancer diagnosis and the disease of denied prison medical careon July 5, 2022 at 9:43 pm
I was informed by a prison doctor here at Virginia’s Nottoway Correctional (sic!) Center (NCC) that I had tested positive for prostate cancer.
- Former Broncos star Demaryius Thomas had CTE. What to know about the disease.on July 5, 2022 at 12:48 pm
Former NFL star was diagnosed with CTE, joining a growing list of late former football players who had the condition. Here is what to know about CTE.
- Flu Vaccination Lowers Risk of Alzheimer’s Disease, Study Suggestson July 5, 2022 at 2:00 am
In a new retrospective cohort study, scientists at the University of Texas Health Science Center at Houston found that, through an uncertain mechanism, influenza vaccination was associated with a 40% ...
- Warfarin May Speed Progression of Aortic Stenosis and Worsen Outcomeson July 4, 2022 at 10:59 am
The findings are not definitive, but they should be considered when choosing an anticoagulant, Samir Kapadia says.
- Invasive management of chronic coronary disease not tied to QoL benefit in patients with CKDon July 4, 2022 at 7:30 am
USA: Among patients with chronic coronary disease (CCD), quality of life (QoL) outcomes may not improve with invasive management in those with poorer kidney function, states research published in JAMA ...
- Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Insights | DelveInsighton June 29, 2022 at 9:02 am
The rising incidence of COPD and the exacerbations associated with it have been instrumental in piquing the interest of pharma players and academia in devising new therapeutic interventions for the ...
- Province advises of additional actions to help prevent the spread of Chronic Wasting Diseaseon June 29, 2022 at 7:30 am
Manitoba Natural Resources and Northern Development is advising of additional management actions to help prevent the spread of Chronic Wasting Disease (CWD).
- Liver fibrosis linked to CV events, survival in NAFLD, chronic kidney diseaseon June 25, 2022 at 3:07 am
Elevated noninvasive markers of liver fibrosis correlated with an increased risk for cardiovascular events, end-stage renal disease and worse survival in patients with chronic kidney disease and ...
- Screening to predict development of kidney disease underutilized, doctors sayon June 24, 2022 at 1:15 am
Finding better ways to determine whether a person is at risk of chronic kidney disease could help introduce lifestyle changes to prevent a condition that affects roughly 38 million adults in the ...
- Prospect of blood test for Parkinson's diseaseon June 23, 2022 at 6:02 am
A research team at the Faculty of Medicine at Kiel University has developed a method that reliably detects protein changes in blood that are typical of Parkinson's disease.
via Bing News
The Latest on: Progression of chronic diseases
via Google News
Add Comment